A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
90
Participants
Timeline
Start Date
December 5, 2016
Primary Completion Date
January 31, 2021
Study Completion Date
May 20, 2022
Conditions
Stage III/IV Melanoma
Interventions
DRUG
Ipilimumab IT
DRUG
Ipilimumab IV
DRUG
Nivolumab IV
Trial Locations (1)
94805
Gustave Roussy, Villejuif
All Listed Sponsors
lead
Gustave Roussy, Cancer Campus, Grand Paris
OTHER
NCT02857569 - A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter